The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.

Authors

Charles L Bennett
Sumimasa Nagai
Andrew C Bennett
Shamia Hoque
Chadi Nabhan
Martin W Schoen
William J Hrushesky
Stefano Luminari
Paul Ray
Paul R Yarnold
Bart Witherspoon
Josh Riente
Laura Bobolts
John Brusk
Rebecca Tombleson
Kevin Knopf
Marc Fishman
Y Tony Yang, George Washington University
Kenneth R Carson
Benjamin Djulbegovic
John Restaino
James O Armitage
Oliver A Sartor

Document Type

Journal Article

Publication Date

2-14-2021

Journal

The Oncologist

DOI

10.1002/onco.13713

Comments

Online ahead of print

APA Citation

Bennett, C., Nagai, S., Bennett, A., Hoque, S., Nabhan, C., Schoen, M., Hrushesky, W., Luminari, S., Ray, P., Yarnold, P., Witherspoon, B., Riente, J., Bobolts, L., Brusk, J., Tombleson, R., Knopf, K., Fishman, M., Yang, Y., Carson, K., Djulbegovic, B., Restaino, J., Armitage, J., & Sartor, O. (2021). The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.. The Oncologist, (). http://dx.doi.org/10.1002/onco.13713

Peer Reviewed

1